Phase 2 N=35 S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Leukemia
Primary: Complete Remission — 52 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=449 A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Mean Change in Visual Acuity From Baseline at the Week 24 Visit — 6.5; 8.8; 10.6 ETDRS Letters
Phase 2 N=90 A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 1 Year Progression Free Survival — 53.7 percentage of participants — p=0.0645
Phase 2 N=64 An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
Stress Urinary Incontinence · Cell Therapy
Primary: Number of Participants That Experienced Biopsy Procedure-related Adverse Events — 3 participants
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 2 N=60 Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen — 1.3; 1.2 cocaine abstinent weeks — p=0.44
Phase 2 N=101 A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma
Asthma
Primary: Forced Expiratory Volume (FEV1) Peak (0-3h) Response — 0.185; 0.261; 0.290; 0.272 Litre — p=0.0002
Phase 2 N=13 The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Pharmacokinetic: Cmax of Betamethasone Dipropionate — NA pg/mL
Phase 2 N=20 A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 2; 1; 2; 0 Participants
Phase 2 N=104 Velcade Consolidation Bone Study
Multiple Myeloma
Primary: Change From Baseline in Bone Mineral Density (BMD) in the Spine at End of Treatment (EOT) — 0.0214; 0.0167 g/mm2
Phase 2 N=756 Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentration Equal to or Above (≥) Cut-off Value. — 186; 181 Participants
Phase 2 N=17 Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Contraception
Primary: Medroxyprogesterone Acetate (MPA) Concentrations — 0.00; 0.27; 0.43; 0.44 ng/mL
Phase 2 N=40 A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)
Mycoses
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) by 12 Weeks or End of Treatment — 26; 46 Percentage of participants
Phase 2 N=40 Naloxone SR Capsules in Patients With Opioid Induced Constipation
Chronic Pain · Opioid Induced Constipation
Primary: Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing. — 8; 5; 4; 6 participants
Phase 2 N=122 A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
Heart Failure, Congestive · Edema
Primary: Body Weight — -0.53; -1.62; -1.35; -1.85 Kg — p=0.0074